HomeCompareBIOR vs VIG

BIOR vs VIG: Dividend Comparison 2026

BIOR yields 909.09% · VIG yields 1.64%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BIOR wins by $8252648.18M in total portfolio value
10 years
BIOR
BIOR
● Live price
909.09%
Share price
$0.22
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8252648.21M
Annual income
$6,784,560,004,057.53
Full BIOR calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.64%
Share price
$210.70
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.4K
Annual income
$179.15
Full VIG calculator →

Portfolio growth — BIOR vs VIG

📍 BIOR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBIORVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BIOR + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BIOR pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BIOR
Annual income on $10K today (after 15% tax)
$77,272.73/yr
After 10yr DRIP, annual income (after tax)
$5,766,876,003,448.90/yr
VIG
Annual income on $10K today (after 15% tax)
$139.33/yr
After 10yr DRIP, annual income (after tax)
$152.28/yr
At 15% tax rate, BIOR beats the other by $5,766,876,003,296.62/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BIOR + VIG for your $10,000?

BIOR: 50%VIG: 50%
100% VIG50/50100% BIOR
Portfolio after 10yr
$4126324.12M
Annual income
$3,392,280,002,118.35/yr
Blended yield
82.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BIOR right now

BIOR
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-109.2
Piotroski
4/9
VIG
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BIOR buys
0
VIG buys
0
No recent congressional trades found for BIOR or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBIORVIG
Forward yield909.09%1.64%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$8252648.21M$32.4K
Annual income after 10y$6,784,560,004,057.53$179.15
Total dividends collected$8138900.96M$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: BIOR vs VIG ($10,000, DRIP)

YearBIOR PortfolioBIOR Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$101,609$90,909.09$11,304$163.92+$90.3KBIOR
2$972,011$863,288.79$12,759$166.33+$959.3KBIOR
3$8,758,157$7,718,105.75$14,382$168.52+$8.74MBIOR
4$74,364,546$64,993,317.91$16,192$170.52+$74.35MBIOR
5$595,318,755$515,748,691.06$18,210$172.34+$595.30MBIOR
6$4,495,664,203$3,858,673,134.79$20,460$173.98+$4495.64MBIOR
7$32,043,550,537$27,233,189,840.42$22,968$175.48+$32043.53MBIOR
8$215,696,715,677$181,410,116,602.38$25,763$176.83+$215696.69MBIOR
9$1,372,045,052,584$1,141,249,566,809.58$28,878$178.05+$1372045.02MBIOR
10$8,252,648,210,323$6,784,560,004,057.53$32,350$179.15+$8252648.18MBIOR

BIOR vs VIG: Complete Analysis 2026

BIORStock

Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

Full BIOR Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this BIOR vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BIOR vs SCHDBIOR vs JEPIBIOR vs OBIOR vs KOBIOR vs MAINBIOR vs DGROBIOR vs NOBLBIOR vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.